Noninvasive cardiac imaging with echocardiography or thallium-201 scintigraphy utilizing pharmacologic agents as alternatives to exercise is gaining popularity. We investigated the physiologic rationale underlying the optimal choice of pharmacologic stress for functional versus perfusion imaging. With the use of an open-chest dog model, a critical stenosis of the left circumflex coronary artery was produced with total ablation of hyperemic response to a 15 sec period of complete occlusion. Regional left ventricular wall thickening was assessed by quantitative two-dimensional echocardiography. Regional myocardial blood flow was determined by microspheres in both the flow-restricted left circumflex area and the control area supplied by the left anterior descending artery.
techniques such as thallium-201 scintigraphy, the coronary flow reserve in different myocardial regions can be estimated. When used in combination with functional imaging techniques such as echocardiography or radionuclide ventriculography, myocardial contractile reserve can also be assessed. However, the attainment of diagnostically useful data requires that a level of exercise be achieved that increases myocardial oxygen demand substantially. For example, McLaughlin et al.' reported that the sensitivity of thallium imaging decreased with submaximal exercise stress compared with the sensitivity with maximal stress. Unfortunately, many patients are physically incapable of sufficiently vigorous exercise. Consequently, pharmacologic interventions such as dobutamine (a positive inotropic agent) or dipyridamole (a coronary vasodilator) have been used as alternatives to exercise. Dobutamine thallium scintigraphy,2 echocardiography,3 and radionuclide ventriculography4 and comparable testing methods in which dipyridamole5-13 is used have all been reported to be useful in the detection or evaluation of patients with suspected coronary artery disease. However, most of these studies involved heterogenous groups of patients with different numbers and severity of coronary lesions, making direct comparison of efficacy difficult.
While dobutamine and dipyridamole differ in their pharmacologic actions, the agent most suitable for perfusion as compared with functional imaging remains undetermined. Accordingly, we conducted an experimental study in which the hemodynamic severity of a single coronary lesion was controlled to determine the magnitude of flow heterogeneity and regional myocardial dysfunction induced by dobutamine versus dipyridamole when a commonly used clinical dose was administered. Since the currently available cardiac imaging techniques mainly rely on the detection of flow disturbances or functional changes, the physiologic data obtained should provide insight into the principles underlying pharmacologic imaging. Application of such principles may help determine the optimal choice of pharmacologic agents when different imaging techniques are used clinically. Methods General preparation. Male mongrel dogs (16 to 24 kg) were anesthetized with intravenous pentobarbital sodium (30 mg/kg) and ventilated with room air delivered by a Harvard respirator via an endotracheal tube. Mean arterial blood pressure was recorded by means of a catheter inserted into the left carotid artery, advanced to the thoracic aorta, and connected to a straingauge pressure transducer (Statham P23Db). The left internal jugular vein was catheterized for drug administration. The left and right femoral arteries were catheterized for withdrawal of reference arterial blood samples used to calculate myocardial blood flow. A lead II electrocardiogram was recorded continuously. A thoracotomy was performed through the left fifth intercostal space, the lung was retracted, and the heart was suspended in a pericardial cradle. A catheter was placed in the left atrium through the atrial appendage for injection of radioactive microspheres. A 2 to 3 cm segment of the left circumflex artery was dissected from the surrounding tissue near its origin, and a calibrated flow probe (Zepeda RA) was placed around the vessel. Phasic and mean coronary blood flows were recorded with the use of an electromagnetic flowmeter (Zepeda SWF4). An adjustable mechanical occluder was placed distal to the left circumflex flow probe and was used to produce coronary stenosis. A silk ligature, placed distal to the mechanical occluder, was used to produce transient total occlusion to zero the electromagnetic flowmeter and produce reactive hyperemic responses.
Experimental protocol. Critical coronary stenosis was produced by adjusting the mechanical occluder until the reactive hyperemic response was abolished while minimally affecting resting coronary blood flow. 1416 Reactive hyperemia was produced with 15 sec complete occlusions produced by tightening the silk ligature placed distal to the occluder. Lesions that reduced coronary blood flow at rest were avoided. The stenosis was considered stable if the reactive hyperemia ratio (hyperemia flow/rest flow) was within 10% on three successive determinations.
After production of the critical stenosis and a stabilization period, a short-axis two-dimensional echocardiogram at the midpapillary muscle level was recorded. Radioactive microspheres were injected via the left atrium for the determination of baseline myocardial blood flow. Each dog then received either intravenous dobutamine (15 ,ug/kg/min) for 10 min or dipyridamole (0.14 mg/kg/min) for 4 min. Immediately before the completion of the dobutamine infusion or 5 min after the dipyridamole infusion, two-dimensional echocardiograms and microsphere injections were repeated. Each dog was then killed by the administration of potassium chloride intravenously.
Echocardiographic analysis. With the use of a minicomputer-based video digitizing system, end-diastolic and end-systolic frames were selected for analysis. The end-diastolic frame selected was the one demonstrating the largest endocardial area and generally corresponded to the onset of the Q wave in lead II of the electrocardiogram. The end-systolic frame selected was the one demonstrating the smallest endocardial area and generally corresponded to the end of the T wave. An observer carefully traced endocardial and epicardial borders directly from the video display with the use of a digitizing tablet for 3 consecutive beats, which were averaged. Percent wall thickening was calculated by use of a radial contraction model and a fixed diastolic center of mass at 22.50 intervals over the full 3600 circumference. [17] [18] [19] For correction of rotation and to serve as an internal landmark for regional flow measures, the midpoint of the posterior papillary muscle was fixed at 1350. Percent wall thickening was calculated as: (endsystolic wall thickness minus end-diastolic wall thickness/enddiastolic wall thickness) x 100%. The mean + SD percent wall thickening was calculated for 3 normal beats, and 95% tolerance limits for normal were established in each individual animal. As illustrated in figures 1 and 2, a function map of the normal range for each individual animal was used for comparison with values obtained after drug infusion. Systolic wall thickening during drug infusion was defined as abnormally reduced if it was less than the lower tolerance established for thickening under control conditions. The point at which the function map obtained during drug infusion intercepted the lower baseline tolerance limit defined the circumferential extent of dysfunction (0) in each animal. The degree of dysfunction was quantitated also as the planimetered area between the functional map and the lower tolerance limit'7-9 ( figure 1 ). In addition, the central ischemic and central nonischemic regions were identified on the function map for statistical comparison of wall thickening and regional myocardial blood flow under control conditions and after drug infusion. Determination of regional myocardial blood flow. The distribution of regional coronary blood flow was determined by the radioactive microsphere technique by methods we have previously described. 15, 16, 20 Carbonized plastic microspheres (15 g.m diameter, New England Nuclear) labeled with 46 SC, 103 Ru, or 141 Ce were used. The mixture was agitated before injection in a vortex mixer for 15 min. Approximately 1 to 2 x 106 spheres were injected into the left atrium, followed by an 8 ml saline wash. A few seconds before each microsphere injection, a timed collection of reference flow from both the femoral arteries was started and maintained at a constant rate (7 ml/min) for 2 min with a Harvard withdrawal pump after completion of the microsphere injection. After completion of the experiment, the heart was excised, washed with saline solution, and fixed in 10% formalin for 24 hr. Two 5 mm slices of myocardium corresponding to the mid posterior papillary muscle level were dissected into 16 22.5 degree full-thickness sectors corresponding to those of the twodimensional echocardiographic study. Each sample was then cut into three pieces of approximate equal thickness from endocardium to epicardium. The location of each piece of tissue was recorded and the tissue samples were weighed and placed in counting vials for assay of radioactivity in a Tractor (Model 1185) gamma scintillation counter. After correcting the counts in each tissue sample for background and overlapping counts with simultaneous equations, blood flow was calculated with the equation18:QM = (Cm X Qr)/Cr, whereQm = myocardial blood flow (ml/min); Cm = counts/min in tissue samples; Qr = withdrawal rate of the reference arterial sample (ml/min); Cr = counts/min in the reference arterial sample. Flow per gram of tissue was calculated by dividing flow by the weight of the appropriate sample. Background and overlap corrections and blood flow calculations were performed on an Apple IL + microcomputer. As illustrated in figures 1 and 2, circumferential blood flow maps were generated with a computer-assisted program.
Statistical analysis. All values are expressed as the mean + SEM. Comparisons of values were made with a two-tailed Student t test or Fisher exact test where appropriate. The probabilities were considered to be statistically significant at p < .05 level.
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Results
Hemodynamics. There was no change in hemodynamics associated with the production of critical stenosis. During the infusion of dobutamine, heart rate increased from 133 ± 9 beats/min to 145 ± 9 beats/ min (p < .02), and mean arterial blood pressure increasedfrom 114 ± 4to 152 ± 14mmHg(p< .03). The rate-pressure product increased by 48.2 + 15.5%, from 14,985 ± 743 to 2261 ± 3251 mm Hg/min (p < .03). During dipyridamole-induced coronary vasodilation, there was no significant change in heart rate (147 + 9 vs 150 ± 9 beats/min, p = NS), whereas mean arterial blood pressure decreased significantly (126 ± 3 vs 90 + 3 mm Hg, p < .001). Accordingly, the rate-pressure product decreased by 26.3 + 2.5%, from 18 ,540 ± 1292 to 13,729 + 1161 mm Hg/min (p < .001).
Myocardial blood flow. During the infusion of dobutamine, blood flow in the left circumflex-supplied myocardium did not change significantly in the subendocardium (0.98 ± 0. 10 vs 1.36 + 0.25 ml/min/g, p = .07), but increased significantly in the midmyocardium (0.85 ± 0.06 vs 1.50 ± 0.24 ml/min/g, p < .02) and in the subepicardium (0.92 ± 0.90 vs 1.65 + 0.32 ml/min/g, p < .03). Regional blood flow in the control region (perfused by the left anterior descending artery) increased significantly in the subendocardium (1.02 + 0. 13 vs 1.67 + 0.26 ml/min/g, p < .007), midmyocardium (0.97 ± 0. 1 1 vs 1.91 ± 0.25 ml/min/g, p < .002), and subepicardium (0.90 + 0.13 vs 1.90 ± 0.32 ml/min/g, p < .003). Thus, as shown in figure 3 , the presence of a critical stenosis attenuated the propensity of dobutamine to increase subendocardial blood flow, despite an increase of perfusion pressure and myocardial oxygen demand. A representative example is shown in figure 1. During dipyridamole-induced coronary vasodilation, blood flow in the left circumflex-supplied myocardium did not change in the subendocardium (1.40 ± 0.11 vs 1.21 ± 0.21 ml/min/g, p = NS) or midmyocardium (1.41 + 0.14 vs 1.48 ± 0.25 ml/min/g, p = NS), but increased significantly in the subepicardium (1.33 ± 0.13 vs 2.14 ± 0.24 ml/min/g, p < .002). Blood flow in the control area increased markedly in the subendocardium (1.73 ± 0.26 vs 4.09 + 0.71 ml/min/g, p < .006), midmyocardium (1.50 ± 0.18 vs 3.51 ± 0.50 ml/min/g, p < .002), and subepicardium (1.28 + 0.11 vs 3.63 + 0.45,p< .001). Thus, as shown in figure 4 , the presence of a critical stenosis limited the effect of coronary vasodilation induced by dipyridamole. A representative example is shown in figure 2 .
Because thallium scintigraphy detects relative blood flow heterogeneity rather than absolute blood flow we analyzed the left anterior descending/left circumflex regional blood flow ratio for all three layers before and after pharmacologic interventions. After dobutamine there was an increase in the blood flow ratio in the 946 subendocardium (1.03 + 0.04 vs 1.27 ± 0.09, p < .03), but it was unchanged in the midmyocardium (1. 15 + 0. 1 1 vs 1.39 ± 0.17, p NS) and subepicardium (0.97 + 0.09 vs 1.22 + 0.11, p = NS). The mean transmural blood flow ratio was increased (1.04 ± 0.06 vs 1.30 + 0.11, p < .05). After dipyridamole, there was a marked and significant increase in the blood flow ratio in the subendocardium (1.22 ± 0.13 vs 3.74 ± 0.51, p < .002), midmyocardium (1.08 ± 0. 1 1 vs 2.63 + 0.34, p < 0.001), and subepicardium (1.00 ± 0.08 vs 1.81 ± 0.26, p < .005). The mean transmural blood flow ratio increased by more than twofold from 1.08 ± 0.07 to 2.47 ± 0.32 (p < .002). Intergroup comparisons showed a significantly higher left anterior descending/left circumflex blood flow ratio after dipyridamole compared with that after dobutamine in the subendocardium (3.74 ± 0.51 vs 1.27 + 0.09, p < .001) and midmyocardium (2.63 + 0.34 vs 1.39 ± 0. 17, p < .007), but a significant difference was not demonstrated in the subepicardium (1.81 ± 0.26 vs 1.22 ± 0.11, p = NS). These findings are graphically illustrated in figure 5 .
Two-dimensional echocardiographic findings. During dobutamine infusion, all dogs (n = 8) developed a regional wall thickening abnormality in the circumflexsupplied myocardial region. The circumferential extent of dysfunction was 97 + 8 degrees and the circumferential degree of dysfunction was 12.2 ± 2.7 cm2. Figure 1 shows a typical example. After dipyridamole, only five (56%) of nine dogs developed regional dysfunction (figure 2). In these five dogs, the circumferential extent of dysfunction was 124 ± 2 degrees, and the circumferential degree of dysfunction was 9.6 ± 6.5 cm2. Intergroup comparisons showed that a larger proportion of dogs displayed regional dysfunction after dobutamine than after dipyridamole (p < .01). However, when dysfunction developed, there was no significant difference either in its circumferential extent or in its degree. During the infusion of dobutamine, percent wall thickening decreased in the left circumflex region (38.8 + 2.0% vs 3.0 ± 14.4%, p < .001), while it increased in the left anterior descending region (47.5 ± 2.5 vs 82.1 + 5. 1 %, p < .001). After dipyridamole, significant changes in percent wall thickening were not observed in the left circumflex region (41.3 ± 4.4% vs 25.6 + 5.6%, p = NS) or in the left anterior descending region (52.0 ± 4.8% vs 59.5 + 8.1%, p = NS) ( figure 6 ).
Dipyridamole-induced regional myocardial dysfunction.
During dipyridamole-induced coronary vasodilation, five (56%) of nine dogs developed regional wall thickening abnormalities while four (44%) did not. Not unexpectedly, changes in percent systolic wall thickening in the left circumflex region did not differ in the nondysfunction group (38.5 ± 6.0% to 39.5 + 7.6%, p = NS), while it decreased considerably in the dysfunction group (43.3 + 6.8% to 14.6 ± 2.8%, p < .01). Although no attempts were made to control heart rate or blood pressure in these two groups, systemic hemodynamic changes were similar. Heart rate remained essentially unchanged in the nondysfunction group (153 ± 21 to 153 ± 20 beats/min) and dysfunction group (143 + 6 to 148 ± 8 beats/min). Comparable decreases in systemic arterial pressures were also observed in both the nondysfunction (125 ± 2 to 94 + 3 mm Hg) and the dysfunction groups (126 + 5 to 88 + 5 mm Hg). Accordingly, similar changes in rate-pressure product were observed in both the nondysfunction (19,186 + 2677 to 14,530 ± 2183 mm Hg/min) and the dysfunction group (18,024 + to 13,088 ± 1327 mm Hg/min).
Since regional dysfunction is considered to be a consequence of ischemia, reductions in left circumflex regional blood flow after dipyridamole were tested with the one-tailed Student t analysis in the two subgroups. In the nondysfunction subgroup, left circumflex subendocardial flow did not decrease (from 1.58 ± 0.12 to 1.82 ± 0.17 ml/min/g, p = NS), while a significant reduction of 36.0 ± 15.8% was noted in the dysfunction subgroup (from 1.26 ± 0.18 to 0.73 ± 0.14 ml/min/g, p < .05). Flow reductions in the midmyocardial region did not occur in either subgroup (nondysfunction subgroup: from 1.70 + 0.16 to 2.70 ± 0.36 ml/min/g, p = NS; dysfunction subgroup: from 1.17 ± 0.19 to 0.94 + 0.13 ml/min/g, p = NS). However, by the two-tailed paired t analysis, subepicardial flow increased significantly only in the nondysfunction subgroup (in the nondysfunction subgroup; a 73.2 + 12.2% increase from 1.08 ± 0.16 to 1.58 ± 0.15 ml/min/g, p = NS). These findings are graphically illustrated in figure 7 .
Discussion
Significant coronary stenosis in man is generally considered to be present when there is at least a 50% to 70% reduction in luminal diameter. By such angiographic criteria, several studies using either dipyridamole or dobutamine in combination with a cardiac imaging modality have reported varying degrees of success in the detection of significant coronary stenosis. For example, the sensitivities of dipyridamole thallium scintigraphy range from 67% to 93% ,5-8 while the sensitivity of dobutamine thallium scintigraphy has been noted to be 94% by Mason et al . 2 Picano et al. 9 12 reported a 56% sensitivity for dipyridamole echocardiography and a 74% sensitivity for high-dose dipyridamole (0.56 mg/kg), and Palac et al.3 reported an 84% sensitivity for dobutamine echocardiography.
Although it is commonly recognized that the concomitant use of either dobutamine or dipyridamole enhances the sensitivity of these diagnostic techniques, the variability of the available data suggests an absence of concensus on the optimal choice of pharmacologic agent relative to the type of imaging modality. Furthermore, these clinical studies generally do not address the potential differences in the physiologic mechanisms that may lead to imaging abnormalities .2 As a result, it is difficult, if not impossible, to determine which pharmacologic agent is superior for functional imaging versus perfusion imaging based on the clinical studies currently available. Furthermore, direct comparison of the studies cited above would not be valid for a number of reasons. First, the proportion of patients with multivessel disease versus single-vessel disease differs. It is well known that with the clinical imaging techniques currently available, detection of multivessel disease is easier 22 23 Second, significant interobserver and intraobserver variability in the interpretation of coronary angiograms is likely to be present among the reported studies.24 There is also the question of whether some of the angiographically "significant" coronary stenoses are truly hemodynamically --significant."25 Third, different criteria were used to inter-pret the thallium scans and the echocardiographic studies, and for the most part, interpretations were qualitative. In view of the inherent limitations of the clinical studies noted above, the present study was designed to determine the effects of these pharmacologic agents in the controlled setting of experimental critical coronary stenosis.
In our study, we characterized coronary stenosis by applying the concept of coronary blood flow reserve previously described by Gould et al. 26 By producing a ..critical" degree of coronary narrowing, we defined the hemodynamic severity of the coronary lesion in functional terms. We used a preparation of single-vessel disease to allow unambiguous interpretation of our flow-function data. Under these experimental conditions, dobutamine given at a dose of 15 ,ug/kg/min for 10 min induced wall thickening abnormalities in all dogs. In contrast, dipyridamole infused at a dose of 0.14 mg/kg/min over 4 min induced wall thickening abnormality in 55% of the dogs studied, in close agreement with the clinical experience of Picano et al. ,9 who found a sensitivity of 56% using a similar dose of dipyridamole.
The difference in the functional response produced by either dobutamine or dipyridamole was significant. Clearly, these two agents induced dysfunction by different mechanisms. Dobutamine increases heart rate, left ventricular pressure, wall stress, inotropic state, and myocardial oxygen demand. In the myocardial region supplied by a critical stenosis, the increase in oxygen demand was not met by an increase in supply because the critical stenosis restricted blood flow, creating a condition of relative ischemia or regional supply-demand imbalance, and regional dysfunction resulted. Dipyridamole, on the other hand, is a vasodilator, which is unlikely to substantially alter myocardial oxygen requirements.27 In the dogs we studied, because heart rate remained unchanged and blood pressure decreased, myocardial oxygen demand probably decreased. Consequently, we attribute the dysfunction evident in five of the nine dogs studied to a decrease in oxygen supply, or absolute (rather than relative) ischemia.28 The fact that subendocardial blood flow decreased significantly in these five dogs after dipyridamole when compared with baseline conditions (figure 7) supports this conclusion. In contrast, in four dogs that did not develop dysfunction, there was no change in subendocardial blood flow. A combination of reduced perfusion pressure and the occurrence of coronary steal 1 5 blood flow heterogeneity was demonstrated, consistent with the work of other investigators.31 32During dobutamine, the heterogeneity of perfusion was much less striking. This is an important consideration since thallium scintigraphy detects relative blood flow differences rather than absolute blood flow. Gould33 has previously demonstrated that a flow disturbance ratio of 2:1 is required to be detected by thallium scintigraphy. By such criteria, none of the eight dogs treated with dobutamine reached such a threshold, while six of the nine dogs given dipyridamole demonstrated blood flow disturbances of such magnitude. Based on the blood flow data alone, we would predict that thallium scintigraphy using dipyridamole would be more sensitive than dobutamine for the detection of critical stenosis. However, coronary blood flow is not the only factor that determines thallium uptake. Cellular metabolic factors such as ischemia could also affect thallium kinetics independent of flow. Nevertheless, Leppo et al.34 provided evidence that thallium kinetics is dominated by coronary flow, whereas hypoxia and contractile state of the myocardium were of lesser importance.
Although we did not perform thallium-201 (201T1) studies, our myocardial blood flow results after dipyridamole are in general agreement with those of Beller et al.,32 who studied 20'Tl kinetics in a similar experimental preparation of coronary stenosis. In their studies, they found that dipyridamole-induced vasodilation in the presence of a critical stenosis resulted in decreased uptake and delayed clearance of intravenously administered 201T1. Since there was increased uptake and more rapid clearance of 201T1 in normally perfused myocardium, this would produce an initial 201T1 defect with delayed redistribution. The results of our experiments, demonstrating that the infusion of dipyridamole results in greatly increased blood flow in normal vessels but no increase in blood flow to the myocardium supplied by the critically stenosed vessel, are also in agreement with a number of other experimental studies using dipyridamole.26' 35 36 However,  in contrast to echocardiographic studies, 12 higher doses of dipyridamole may not increase the sensitivity of thallium imaging.5 Although we did not examine 201T1 kinetics or perform thallium cardiac imaging, our previous experience37' 38 and the experience of others33' 34 suggest that our observations concerning myocardial blood flow should be closely related to the results of thallium scintigraphy since initial myocardial uptake of thallium is primarily a function of coronary flow.
There is one methodologic issue that deserves com-ment. In our study, regional left ventricular function was assessed by the measurement of regional wall thickening by two-dimensional echocardiography with the use of a fixed diastolic center of mass. Measures of wall thickening, by virtue of the fact that they are calculated as relative indexes, are less coordinate dependent and are less influenced by the placement of the center of mass than are measures of endocardial motion, particularly in the setting of regional ischemia.18 However, Force et al. 39 have demonstrated wall thickening measures using a floating center of mass may contribute to an overestimation of infarct size. We used a fixed center of mass, which should produce less methodologic difficulty, particularly during myocardial ischemia. Our methodologic approach is supported by studies from our laboratory in which we compared wall thickening abnormalities using our approach directly to measures of myocardial risk area and coronary flow. 18 19 Furthermore, our flow-function results using two-dimensional echocardiography have compared favorably to independent results obtained by sonomicrometer techniques. 40 We should also comment on several potential limitations of our study. Although the experimental critical stenosis is a well-established technique,'1'6' 26, 32 the severity of the stenosis may potentially change during pharmacologic interventions because perfusion pressure and transstenotic gradients may be altered. Although we did not measure transstenotic gradients, we did measure myocardial blood flow in all animals and used each dog as its own control, minimizing the impact of this potential limitation. Another limitation is that it is possible that we may have obtained different results with different doses of the pharmacologic interventions. For example, in the clinical studies of Picano et al. 12 high-dose dipyridamole echocardiography yielded a higher sensitivity (74%) than the lower dose that was used in our studies. However, examining the dose-response relationships ofthe pharmacologic interventions was not the goal of our study and thus was not done. Furthermore, it is possible that the effect of collateral vessels may modify the pharmacologic stress results'3 and this also was not explored in this study. In addition, our experimental results may not be valid in the setting of complex multivessel coronary disease. For all of these reasons, our conclusions should be extrapolated with caution to the clinical situation.
One additional limitation of our study relates to the absence of continuous echocardiographic monitoring. Although left ventricular function was frequently monitored visually throughout our experimental protocol, only specific time points were recorded on videotape for subsequent computer-assisted analysis. As a result, transient left ventricular wall thickening abnormalities that may have occurred after completion of the dipyridamole infusion may not have been detected and this may have minimized the sensitivity of the dipyridamole intervention. However, previous studies have demonstrated that the maximal changes in the coronary blood flow after dipyridamole are observed within the first few minutes.27 41 In addition, clinical echocardiographic studies found that regional transient asynergy usually occurred within 5 min of administration of dipyridamole.12 In view of these considerations, our quantitative echocardiographic evaluations were done at 5 min after infusion and thus it is unlikely that transient wall thickening abnormalities were not detected.
In conclusion, while dobutamine and dipyridamole have both been used successfully in conjunction with imaging techniques to detect coronary artery disease, these two agents operate by different mechanisms.
Using a preparation of single-vessel disease in which a critical stenosis was characterized on the basis of coronary flow reserve, we were able to show that dobutamine is likely to be superior for imaging based on regional contractile function, while dipyridamole is likely to be superior for perfusion imaging. As determined by quantitative echocardiographic methods, dobutamine was extremely effective in producing wall thickening abnormalities in the regions supplied by a critical stenosis, whereas dipyridamole produced large differences in regional perfusion between normally perfused and flow-restricted areas. It should be acknowledged that our experimental observations apply only to our single stenosis model and to the dosage regimen used; the results could be potentially different given the more complex clinical condition of multivessel disease. Nevertheless, these physiologic data should provide insight to a more rational approach to pharmacologic imaging in man.
